|
|
Jeremy B. Swann, Mark J. Smyth
J Clin Invest. 2007;
117(5):1137
doi:10.1172/JCI31405
Abstract |
Full text
| PDF
T
he ability of the immune system to identify and destroy nascent tumors, and to thereby function as a primary defense against cancer, has been debated for many decades. Recent findings by a number of investigators in both mouse models of cancer and humans with cancer now offer compelling evidence that particular immune cell types, effector molecules, and pathways can sometimes collectively function as extrinsic tumor suppressor mechanisms. This work provides the basis for further study of natural immunity to cancer and for rational use of this information in the design of immunotherapies in combination with other conventional cancer treatments.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(32)
| Title and authors |
Publication |
Year |
Adjuvant immunotherapy for non-small cell lung cancer
Zachary C.G. Tucker, Benjamin A. Laguna, Edmund Moon, Sunil Singhal
|
Cancer Treatment Reviews
|
2012 |
Oral cancer treatment and immune targets – A role for dendritic cells?
Hans-Robert Metelmann, Peter Hyckel, Fred Podmelle
|
Journal of Cranio-Maxillofacial Surgery
|
2012 |
The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
Mark P Chao, Irving L Weissman, Ravindra Majeti
|
Current Opinion in Immunology
|
2012 |
Low C3 levels is associated with neutropenia in a proportion of patients with myelodysplastic syndrome: retrospective analysis
Ki-Jo Kim, Seung-Ki Kwok, Yun-Jung Park, Wan-Uk Kim, Chul-Soo Cho
|
International Journal of Rheumatic Diseases
|
2012 |
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies
A. J. Christiansen, A. West, K.-M. Banks, N. M. Haynes, M. W. Teng, M. J. Smyth, R. W. Johnstone
|
Proceedings of the National Academy of Sciences
|
2011 |
The Potential Role of CD133 in Immune Surveillance and Apoptosis: A Mitochondrial Connection?
Renata Zobalova, Katerina Prokopova, Marina Stantic, Michael Stapelberg, Lan-Feng Dong, Stephen J. Ralph, Emmanuel Akporiaye, Jiri Neuzil
|
Antioxidants & Redox Signaling
|
2011 |
Potential targets for pancreatic cancer immunotherapeutics
Lindzy F Dodson, William G Hawkins, Peter Goedegebuure
|
Immunotherapy
|
2011 |
Behavior of Circulating CD4+CD25+Foxp3+ Regulatory T Cells in Colon Cancer Patients Undergoing Surgery
Ausilia Sellitto, Gennaro Galizia, Umberto De Fanis, Eva Lieto, Anna Zamboli, Michele Orditura, Ferdinando De Vita, Riccardo Giunta, Giacomo Lucivero, Ciro Romano
|
J Clin Immunol
|
2011 |
Colorectal cancer vaccines in clinical trials
Frank M Speetjens, Eliane CM Zeestraten, Peter JK Kuppen, Cornelis JM Melief, Sjoerd H van der Burg
|
Expert Rev Vaccines
|
2011 |
Tumor Promotion via Injury- and Death-Induced Inflammation
Ali Kuraishy, Michael Karin, Sergei I. Grivennikov
|
Immunity
|
2011 |
|